Paul Audhya Sells 1,163 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 1,163 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $15.00, for a total transaction of $17,445.00. Following the transaction, the insider directly owned 133,087 shares in the company, valued at $1,996,305. This trade represents a 0.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $15.83 on Friday. The firm has a 50 day simple moving average of $15.50 and a 200-day simple moving average of $13.88. The stock has a market cap of $800.14 million, a price-to-earnings ratio of -4.01 and a beta of -0.19. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.23 and a 1-year high of $19.00.

Analysts Set New Price Targets

KALV has been the topic of a number of research analyst reports. HC Wainwright lifted their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Needham & Company LLC raised their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.40.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Emerald Advisers LLC increased its stake in KalVista Pharmaceuticals by 30.2% during the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after purchasing an additional 313,205 shares during the period. Emerald Mutual Fund Advisers Trust boosted its stake in shares of KalVista Pharmaceuticals by 26.4% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock valued at $8,693,000 after purchasing an additional 160,759 shares during the period. Stonepine Capital Management LLC grew its holdings in shares of KalVista Pharmaceuticals by 364.0% in the second quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock valued at $1,130,000 after purchasing an additional 78,450 shares in the last quarter. F m Investments LLC grew its holdings in shares of KalVista Pharmaceuticals by 263.8% in the second quarter. F m Investments LLC now owns 182,262 shares of the specialty pharmaceutical company’s stock valued at $2,060,000 after purchasing an additional 132,165 shares in the last quarter. Finally, Panagora Asset Management Inc. increased its stake in KalVista Pharmaceuticals by 307.0% during the 2nd quarter. Panagora Asset Management Inc. now owns 292,593 shares of the specialty pharmaceutical company’s stock worth $3,308,000 after buying an additional 220,697 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.